Publications
- PCSK9 inhibitors - new possibilities in the treatment of hypercholesterolemia: For which patients will be indicated? Czech atherosclerosis society statement2016 | Faculty of Medicine in Pilsen, First Faculty of Medicine, Third Faculty of Medicine, Faculty of Medicine in Hradec Králové
- Combined hypolipidemic treatment in patients with high cardiovascular (CV) risk2009 | First Faculty of Medicine
- Hypolipidemic drugs and diabetes mellitus2009 | First Faculty of Medicine
- Intestinal mucosal damage monitoring in cancer patients treated with cytotoxic drugs2006 | Faculty of Medicine in Hradec Králové
- The Impact of Convertase Subtilisin/Kexin Type 9 Monoclonal Antibodies with and without Apheresis on Platelet Aggregation in Familial Hypercholesterolemia2024 | Faculty of Medicine in Hradec Králové, Faculty of Pharmacy in Hradec Králové
- 2023 Update on European Atherosclerosis Society Consensus Statement on Homozygous Familial Hypercholesterolaemia: new treatments and clinical guidance2023 | Faculty of Medicine in Pilsen, First Faculty of Medicine, Third Faculty of Medicine, Faculty of Medicine in Hradec Králové, Central Library of Charles University, Second Faculty of Medicine
- Statement CSAT on Consensus statement of the European Atherosclerosis Society: Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis2023 | Faculty of Medicine in Pilsen, First Faculty of Medicine, Faculty of Medicine in Hradec Králové, Central Library of Charles University
- Sex-Related Differences in Platelet Aggregation: A Literature Review Supplemented with Local Data from a Group of Generally Healthy Individuals2023 | Faculty of Medicine in Hradec Králové, Faculty of Pharmacy in Hradec Králové
- The Effect of 4-Methylcatechol on Platelets in Familial Hypercholesterolemic Patients Treated with Lipid Apheresis and/or Proprotein Convertase Subtilisin Kexin 9 Monoclonal Antibodies2023 | Faculty of Medicine in Hradec Králové, Faculty of Pharmacy in Hradec Králové
- Regional differences in physicians' behavior and factors influencing the intensity of PCSK9 inhibitor therapy with alirocumab: a subanalysis of the ODYSSEY APPRISE study2023 | First Faculty of Medicine, Faculty of Medicine in Hradec Králové
Loading network view...